Skip to main content

Table 3 Biodistribution results of 177Lu-SS-03 and 99mTc-SS-04 in nude mice bearing HEK293-rsst2 tumour xenografts. Data expressed as %IA/g (percentage of injected activity per gram) and presented as mean ± SD (n = 3–5)

From: The tetraamine chelator outperforms HYNIC in a new technetium-99m-labelled somatostatin receptor 2 antagonist

Organs

1 h

4 h

4 h blocking*

24 h

177Lu-SS-03

 Blood

0.57 ± 0.04

0.21 ± 0.04

0.07 ± 0.02

0.07 ± 0.04

 Heart

0.69 ± 0.12

0.38 ± 0.07

0.11 ± 0.01

0.11 ± 0.04

 Liver

3.00 ± 0.66

1.75 ± 0.22

1.04 ± 0.09

0.47 ± 0.07

 Spleen

1.51 ± 0.19

1.42 ± 0.77

0.28 ± 0.04

0.33 ± 0.06

 Lung

13.24 ± 4.49

6.71 ± 1.37

0.59 ± 0.11

0.74 ± 0.22

 Kidney

15.15 ± 1.86

17.04 ± 1.81

20.24 ± 4.30

7.35 ± 1.66

 Stomach

48.74 ± 13.11

30.21 ± 4.25

0.37 ± 0.06

6.02 ± 1.40

 Intestine

3.13 ± 1.16

2.28 ± 0.31

0.24 ± 0.03

0.27 ± 0.06

 Adrenal

3.70 ± 0.63

2.90 ± 0.46

0.06 ± 0.03

1.16 ± 0.46

 Pancreas

72.61 ± 13.77

54.49 ± 7.28

0.24 ± 0.07

3.03 ± 0.62

 Muscle

0.22 ± 0.06

0.12 ± 0.02

0.06 ± 0.00

0.07 ± 0.02

 Bone

4.11 ± 0.53

2.77 ± 1.06

0.12 ± 0.03

1.25 ± 0.16

 Tumour

23.64 ± 1.28

31.68 ± 4.00

11.15 ± 1.93

26.32 ± 4.42

99mTc-SS-04

 Blood

1.85 ± 0.41

0.22 ± 0.03

0.22 ± 0.01

0.03 ± 0.01

 Heart

1.42 ± 0.30

0.25 ± 0.06

0.23 ± 0.02

0.09 ± 0.01

 Liver

7.18 ± 0.40

5.13 ± 0.51

4.07 ± 0.65

1.87 ± 0.33

 Spleen

2.09 ± 0.34

0.85 ± 0.08

0.63 ± 0.02

0.41 ± 0.11

 Lung

15.93 ± 2.69

2.03 ± 0.14

2.00 ± 0.37

0.54 ± 0.10

 Kidney

49.82 ± 4.31

25.56 ± 1.01

18.48 ± 3.66

6.31 ± 1.82

 Stomach

11.13 ± 2.98

1.99 ± 0.39

0.56 ± 0.03

0.62 ± 0.14

 Intestine

2.12 ± 0.57

0.57 ± 0.06

0.42 ± 0.03

0.16 ± 0.02

 Adrenal

3.17 ± 0.69

0.99 ± 0.20

0.37 ± 0.10

0.50 ± 0.13

 Pancreas

15.58 ± 0.82

1.16 ± 0.86

0.33 ± 0.06

0.31 ± 0.11

 Muscle

0.64 ± 0.13

0.12 ± 0.02

0.12 ± 0.02

0.05 ± 0.03

 Bone

3.15 ± 0.72

0.92 ± 0.15

0.40 ± 0.01

0.44 ± 0.23

 Tumour

47.14 ± 7.23

47.24 ± 7.96

14.17 ± 1.69

32.51 ± 0.78

  1. *Pre-injection with 20 nmol of unlabelled peptide (SS-03 or SS-04)